T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Active, not recruiting · NCT04457596 · Registry updated 2026-06-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | HER2 positive breast carcinoma, invasive breast carcinoma, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-06-15 | NCT04457596 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Alliance for Clinical Trials in Oncology | 79 |
| National Cancer Institute (NCI) | 3015 |
| Seagen Inc. | 31 |
1,176 results · Page 1 of 48
Research sites
Swipe the table sideways for more columns.